Cash and Short Term Investments (Quarterly) Chart

Historical Cash and Short Term Investments (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 125.90M
March 31, 2026 169.53M
December 31, 2025 209.86M
September 30, 2025 72.04M
June 30, 2025 104.16M
March 31, 2025 138.85M
December 31, 2024 168.07M
September 30, 2024 197.86M
June 30, 2024 219.22M
March 31, 2024 245.92M
December 31, 2023 285.51M
September 30, 2023 345.67M
June 30, 2023 378.67M
March 31, 2023 421.19M
December 31, 2022 478.93M
September 30, 2022 537.40M
June 30, 2022 597.88M
March 31, 2022 671.73M
Date Value
December 31, 2021 731.51M
September 30, 2021 799.25M
June 30, 2021 880.87M
March 31, 2021 928.98M
December 31, 2020 968.97M
September 30, 2020 380.45M
June 30, 2020 417.13M
March 31, 2020 421.86M
December 31, 2019 336.48M
September 30, 2019 60.60M
June 30, 2019 68.10M
March 31, 2019 81.08M
December 31, 2018 88.25M
September 30, 2018 11.59M
June 30, 2018
March 31, 2018
December 31, 2017 1.395M

Cash and Short Term Investments Definition

Represents the sum of cash and short term investments.

Read full definition.

Cash and Short Term Investments (Quarterly) Range, Past 5 Years

View Cash and Short Term Investments (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash and Short Term Investments (Quarterly) Benchmarks

View Cash and Short Term Investments (Quarterly) Benchmarks
Start Trial
Regeneron Pharmaceuticals, Inc. 8.005B
AbbVie, Inc. 6.569B
Mirum Pharmaceuticals, Inc. 438.29M
ACADIA Pharmaceuticals, Inc. 956.47M
Alnylam Pharmaceuticals, Inc. 3.308B